Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

PMV Pharmaceuticals, Inc. (PMVP)

$1.24 -6.77% NASDAQ: PMVP · 15-min delayed
  • PRINCETON, New Jersey
  • Public · NASDAQ: PMVP
  • 54 employees
$59.7MMarket cap
-$77.7MNet income
54Employees
PMVPNASDAQ
2020IPO

About PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Net income
-$77.7M
Total assets
$116.6M
Market cap
$59.7M
Operating margin
-1360.4%
Net margin
-1226.8%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$6.3M
Operating expenses
$86.2M
Operating income
-$86.2M
Income tax
-$2.2M
Net income
-$77.7M
EPS (basic)
$-1.48
EPS (diluted)
$-1.48

Balance sheet

Total assets
$116.6M
Current assets
$115.2M
Total liabilities
$11.8M
Current liabilities
$11.4M
Shareholders’ equity
$104.7M

Cash flow

Operating cash flow
-$73.6M
Investing cash flow
$70.2M
Financing cash flow
$505.0K
Net cash flow
-$2.9M

Statements via Polygon.io (SEC filings)

NASDAQ: PMVP
$1.24 -6.77%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$1.02 $1.80

52-week range

Market cap
$59.7M
EPS (diluted)
$-1.48
Shares outstanding
48.2M
Open
Day range
Prev close
Volume
IPO date
Sep 25, 2020

PMV Pharmaceuticals, Inc. (PMVP) Stock Price

  • Reported a net loss of $77.7M.
  • Revenue grew 873% from FY2020 to FY2025.
  • Trading 31% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review PMV Pharmaceuticals, Inc..

Write a review
Newsroom

News about PMV Pharmaceuticals, Inc.

News & sentiment via Polygon.io

FAQ

PMV Pharmaceuticals, Inc.: frequently asked questions

Is PMV Pharmaceuticals, Inc. an American company?

PMV Pharmaceuticals, Inc. is a US-based company headquartered in Princeton, New Jersey, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is PMV Pharmaceuticals, Inc. headquartered?

PMV Pharmaceuticals, Inc. is headquartered in Princeton, New Jersey, United States.

Is PMV Pharmaceuticals, Inc. publicly traded?

Yes — PMV Pharmaceuticals, Inc. is a publicly traded company. Its stock trades under the ticker symbol PMVP on the NASDAQ.

What does PMV Pharmaceuticals, Inc. do?

PMV Pharmaceuticals, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →